The first reversal agent for a novel oral anticoagulant is now available in Australia. Idarucizumab (Praxbind) manufactured by Boehringer Ingelheim is expected to be used in patients taking dabigatran who require reversal of anticoagulation for emergency surgery or who have life-threatening or uncontrolled bleeding. Its registration is based on the results from the Phase III ...
Already a member?
Enter your email to keep reading.